Cargando…

Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)

OBJECTIVE: To assess the reproducibility and clinical utility of clustering-based subtyping of patients with type 2 diabetes (T2D) and established cardiovascular (CV) disease. METHODS: The cardiovascular outcome trial SAVOR-TIMI 53 (n = 16,492) was used. Analyses focused on T2D patients with establi...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoki, Yasunori, Hamrén, Bengt, Clegg, Lindsay E., Stahre, Christina, Bhatt, Deepak L., Raz, Itamar, Scirica, Benjamin M., Oscarsson, Jan, Carlsson, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604302/
https://www.ncbi.nlm.nih.gov/pubmed/34797832
http://dx.doi.org/10.1371/journal.pone.0259372
_version_ 1784601928854929408
author Aoki, Yasunori
Hamrén, Bengt
Clegg, Lindsay E.
Stahre, Christina
Bhatt, Deepak L.
Raz, Itamar
Scirica, Benjamin M.
Oscarsson, Jan
Carlsson, Björn
author_facet Aoki, Yasunori
Hamrén, Bengt
Clegg, Lindsay E.
Stahre, Christina
Bhatt, Deepak L.
Raz, Itamar
Scirica, Benjamin M.
Oscarsson, Jan
Carlsson, Björn
author_sort Aoki, Yasunori
collection PubMed
description OBJECTIVE: To assess the reproducibility and clinical utility of clustering-based subtyping of patients with type 2 diabetes (T2D) and established cardiovascular (CV) disease. METHODS: The cardiovascular outcome trial SAVOR-TIMI 53 (n = 16,492) was used. Analyses focused on T2D patients with established CV disease. Unsupervised machine learning technique called “k-means clustering” was used to divide patients into subtypes. K-means clustering including HbA1c, age of diagnosis, BMI, HOMA2-IR and HOMA2-B was used to assign clusters to the following diabetes subtypes: severe insulin deficient diabetes (SIDD); severe insulin-resistant diabetes (SIRD); mild obesity-related diabetes (MOD); mild age-related diabetes (MARD). We refer these subtypes as “clustering-based diabetes subtypes”. A simulation study using randomly generated data was conducted to understand how correlations between the above variables influence the formation of the cluster-based diabetes subtypes. The predictive utility of clustering-based diabetes subtypes for CV events (3-point MACE), renal function reduction (eGFR decrease >30%) and diabetic disease progression (introduction of additional anti-diabetic medication) were compared with conventional risk scores. Hazard ratios (HR) were estimated by Cox-proportional hazard models. RESULTS: In the SAVOR-TIMI 53 trial based dataset, the percentage of the clustering-based T2D subtypes were; SIDD (18%), SIRD (17%), MOD (29%), MARD (37%). Using the simulated dataset, the diabetes subtypes could be largely reproduced from a log-normal distribution when including known correlations between variables. The predictive utility of clustering-based diabetic subtypes on CV events, renal function reduction, and diabetic disease progression did not show an advantage compared to conventional risk scores. CONCLUSIONS: The consistent reproduction of four clustering-based T2D subtypes can be explained by the correlations between the variables used for clustering. Subtypes of T2D based on clustering had limited advantage compared to conventional risk scores to predict clinical outcome in patients with T2D and established CV disease.
format Online
Article
Text
id pubmed-8604302
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-86043022021-11-20 Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial) Aoki, Yasunori Hamrén, Bengt Clegg, Lindsay E. Stahre, Christina Bhatt, Deepak L. Raz, Itamar Scirica, Benjamin M. Oscarsson, Jan Carlsson, Björn PLoS One Research Article OBJECTIVE: To assess the reproducibility and clinical utility of clustering-based subtyping of patients with type 2 diabetes (T2D) and established cardiovascular (CV) disease. METHODS: The cardiovascular outcome trial SAVOR-TIMI 53 (n = 16,492) was used. Analyses focused on T2D patients with established CV disease. Unsupervised machine learning technique called “k-means clustering” was used to divide patients into subtypes. K-means clustering including HbA1c, age of diagnosis, BMI, HOMA2-IR and HOMA2-B was used to assign clusters to the following diabetes subtypes: severe insulin deficient diabetes (SIDD); severe insulin-resistant diabetes (SIRD); mild obesity-related diabetes (MOD); mild age-related diabetes (MARD). We refer these subtypes as “clustering-based diabetes subtypes”. A simulation study using randomly generated data was conducted to understand how correlations between the above variables influence the formation of the cluster-based diabetes subtypes. The predictive utility of clustering-based diabetes subtypes for CV events (3-point MACE), renal function reduction (eGFR decrease >30%) and diabetic disease progression (introduction of additional anti-diabetic medication) were compared with conventional risk scores. Hazard ratios (HR) were estimated by Cox-proportional hazard models. RESULTS: In the SAVOR-TIMI 53 trial based dataset, the percentage of the clustering-based T2D subtypes were; SIDD (18%), SIRD (17%), MOD (29%), MARD (37%). Using the simulated dataset, the diabetes subtypes could be largely reproduced from a log-normal distribution when including known correlations between variables. The predictive utility of clustering-based diabetic subtypes on CV events, renal function reduction, and diabetic disease progression did not show an advantage compared to conventional risk scores. CONCLUSIONS: The consistent reproduction of four clustering-based T2D subtypes can be explained by the correlations between the variables used for clustering. Subtypes of T2D based on clustering had limited advantage compared to conventional risk scores to predict clinical outcome in patients with T2D and established CV disease. Public Library of Science 2021-11-19 /pmc/articles/PMC8604302/ /pubmed/34797832 http://dx.doi.org/10.1371/journal.pone.0259372 Text en © 2021 Aoki et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Aoki, Yasunori
Hamrén, Bengt
Clegg, Lindsay E.
Stahre, Christina
Bhatt, Deepak L.
Raz, Itamar
Scirica, Benjamin M.
Oscarsson, Jan
Carlsson, Björn
Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
title Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
title_full Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
title_fullStr Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
title_full_unstemmed Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
title_short Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
title_sort assessing reproducibility and utility of clustering of patients with type 2 diabetes and established cv disease (savor -timi 53 trial)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604302/
https://www.ncbi.nlm.nih.gov/pubmed/34797832
http://dx.doi.org/10.1371/journal.pone.0259372
work_keys_str_mv AT aokiyasunori assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial
AT hamrenbengt assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial
AT clegglindsaye assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial
AT stahrechristina assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial
AT bhattdeepakl assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial
AT razitamar assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial
AT sciricabenjaminm assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial
AT oscarssonjan assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial
AT carlssonbjorn assessingreproducibilityandutilityofclusteringofpatientswithtype2diabetesandestablishedcvdiseasesavortimi53trial